The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development program as we advance to Phase III trials. What were the key findings from the CT388-103 Phase II trial
Pharmaceutics 15, 2042
Here is the practical comparison researchers rely on
What this 1-day workshop will cover: How to safely dose and monitor your patients weight loss How to recognize non responding patients and what to do next How to support your patients weight loss with GLP1s and supplements 8:00 am Weight Loss Introduction James LaValle, RPh, CCN, MT Metaflammation and understanding Mitochondrial interference Factors in metaflammation 9:00 am Insulin Resistance James LaValle, RPh, CCN, MT Cell signaling Impact of low thyroid Impact of Cortisol and stress Impact of environmental burden - Pesticides - Heavy metals - Biotoxins Key nutrients Peptides GLP-1/GIP agonists 10:30 am Managing Cortisol and Thyroid Hormone Gordon Crozier, DO Working within circadian timing Strategies for thyroid support Key nutrients, Peptides and compounded Rx 11:30 am Sex Hormones and Weight Loss Gordon Crozier, DO Testosterone Estrogens Estradiol/Estriol Progesterone balance Key nutrients 1:30 pm Exercise: Preserving Muscle During Weight Loss Cliff Edberg, RD, CPT 2:00 pm Gut-Immune-Brain Connection James LaValle, RPh, CCN, MT Impact of the Microbiome on hunger signaling and satiety Reward cascade and Hedonic Urge the dopamine connection Correcting for Gut permeability Key nutrients, peptides and compounded Rx 3:30 pm Diet: The Most Effective Diet for Lean Mass Retention and Glucose Regulation Laura LaValle, RDN, LD Impact of food sensitivities and allergies 4:30 pm Putting It All Together James LaValle, RPh, CCN, MT Options for other compounds when GLP-1 are not indicated or tolerated
